Search for: "Bayer Corp"
Results 421 - 440
of 505
Sorted by Relevance
|
Sort by Date
24 May 2007, 10:40 am
Bayer Corp., 398 F.3d 640, 643 (7th Cir. 2005) (applying Illinois law); Thomas v. [read post]
17 Feb 2010, 5:10 am
Merck, Sharp & Dohme Corp. [read post]
22 Apr 2016, 3:51 pm
Bayer Corp., 727 F.3d 300, 355 (3d Cir. 2013)],where the class consists of anybody who laid eyes on a website’s terms of use? [read post]
27 Jul 2015, 8:53 am
Bayer Corp. [read post]
15 Apr 2014, 6:30 am
Bayer Corp., 131 S. [read post]
6 Feb 2015, 9:18 am
Bayer Corp., 131 S. [read post]
7 Dec 2011, 8:31 am
Bayer Corp., also written by Judge Posner. [read post]
28 Apr 2014, 10:00 am
Dukes, 564 U.S. 277 (2011), and Comcast Corp. v. [read post]
6 Jan 2017, 7:17 am
Bayer Corp., 727 F.3d 300 (3d Cir. 2013), the Third Circuit added a second prong to the ascertainability requirement—that there must be “a reliable and administratively feasible” method for ascertaining proposed class members, Carrera, 727 F.3d at 308, so they can be notified of their right to opt out, fraudulent claims can be policed, and defendants may exercise their due process right to challenge the proof used to demonstrate class membership. [read post]
6 Feb 2007, 10:05 am
In Microsoft Corp. v. [read post]
20 Mar 2017, 9:31 am
Bayer Corp., 727 F.3d 300, 308 (3d Cir. 2013). [read post]
6 Feb 2015, 9:18 am
Bayer Corp., 131 S. [read post]
3 Jun 2011, 6:00 am
TransAmerican Natural Gas Corp. v. [read post]
7 Feb 2019, 12:08 pm
Bayer Corp., in the Eastern District of Texas; and United States ex rel. [read post]
26 Jul 2017, 7:01 pm
Bayer Corp., 564 U.S. 299. [read post]
1 Apr 2010, 3:04 am
USPTO and Myriad Genetics (Docket Report) (Peter Zura's 271 Patent Blog) (Inventive Step) (Patently-O) (Holman's Biotech IP Blog) (Patent Docs) (Ladas & Parry) (Tech Transfer Blog) (ipwars.com) (Ars Technica) (BlawgIT) (IP Watch) (The Prior Art) US: Study suggests USPTO erred in broad claims of Myriad BRCA1 patent (Tech Transfer Blog) (Patent Docs) US: CAFC confirms written description requirement in Ariad v Lilly (IP Law Blog) (IP Osgoode) (IP Spotlight) (Ars Technica) US: Justifying… [read post]
12 Jan 2022, 8:38 am
“In 2012, India’s first ever compulsory license was granted by the Indian Patent Office to Natco Pharma for generic production of Bayer Corp’s Nexaver® (Sorafenib Tosylate), a life-saving medicine used for treating liver and kidney cancer. [read post]
29 Apr 2015, 10:52 am
Bayer Corp., 727 F.3d 300, 308 n.2 (3d Cir. 2013)) (citations omitted). [read post]
23 May 2011, 1:54 pm
Court of Appeals for the Eleventh Circuit upheld in Schering-Plough Corp. v. [read post]
15 Apr 2010, 4:56 am
Bayer AG, 235 Ill. 2d 544, 550 (2009)). [read post]
